Futura Medical Regulatory News (FUM)

Futura Medical plc

("Futura" or "the Company")

 CSD500 Dossier Submitted for Approval

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, is pleased to announce that the updated dossier for the marketing authorisation of CSD500, which is set to be launched as a Durex®-branded condom by SSL International plc (SSL), has now been submitted for CE mark approval. It is expected that this will allow the CE mark approval process to be completed later in 2010.

The award of the CE mark will represent a major milestone in the development and commercialisation of CSD500. Preparation for the commercial launch by SSL is underway. Futura will continue to support SSL wherever appropriate but the timetable, the launch strategy and the product's name within the Durex® range will all be managed by SSL.

James Barder, Futura's Chief Executive, said: "The submission of the regulatory dossier for CSD500 is a major milestone for Futura, as the Company is now on the threshold of receiving its first recurring revenues from royalty payments on product sales. We are close to completing our work on CSD500 as the timing and strategy for the launch of the product are under the control of SSL. However, we will continue to support SSL as appropriate as we make progress on the other opportunities within our pipeline of potential products."

For any further information please contact:

Notes to Editors

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com